DGAP-News

Sangui BioTech International Inc.: Preclinical trials demonstrate: Sangui hemoglobin preparation improves oxygen supply of vital organs

DGAP-News: Sangui BioTech International Inc. / Key word(s): Study
results
Sangui BioTech International Inc.: Preclinical trials demonstrate:
Sangui hemoglobin preparation improves oxygen supply of vital organs

11.11.2014 / 15:00

---------------------------------------------------------------------

Sangui Biotech: Preclinical trials demonstrate: Sangui hemoglobin
preparation improves oxygen supply of vital organs

Witten, Germany, November 11, 2014 - A possible success in treating septic
shock has now been attained by the research team embracing SanguiBioTech
GmbH, the Excellence Cluster Cardio Pulmonary System (ECCPS) and TransMIT
Gesellschaft für Technologietransfer mbH. Preclinical trials at Giessen
University underpin that a hemoglobin based product developed by
SanguiBioTech is apt to improve the oxygen supply of vital organs. It is
now being supposed that Sangui's hemoglobin-based artificial oxygen
carriers may interrupt the self-perpetuating mechanism of septic shock,
that has so far been highly resistant to treatment, and may thus ultimately
reduce the high mortality rates.

A septic shock is the life threatening final phase of a sepsis. The blood
circulation, else exactly tuned to meet the needs of the body, begins to
severely malfunction which results in deficient oxygen supply of the body
tissue. This hypoxia induces a progressional intoxication of the body with
bacteria and bacteria debris. Modern medical science has not yet identified
suitable therapies to effectively fight this self-perpetuating mechanism of
septicemia, which, therefore, results in mortality rates of 50 to 60
percent.

Preclinical trials in Giessen now demonstrate that an oxygen-carrying
hemoglobin liquid in the abdomen did significantly improve the oxygen
supply to the intestines. This is likely to be a decisive new therapeutic
approach to disrupting this lethal loop. The preclinical trials are being
continued as planned, extending the scope to additional indications such as
ARDS (acute respiratory distress syndrome) and further hemoglobin
preparations as developed by SanguiBioTech.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

ECCPS is an organization set up jointly by the universities of Frankfurt
and Giessen together with the Max Planck Institute for Heart and Lung
Research in Bad Nauheim. It ranks among the world's leading organizations
of this type. This unique centre for translational medicine combines
innovative medical research in the field of heart and lung diseases with
their practical advancements based on preclinical and clinical studies. Its
aim is to work together with industry on developing innovative drugs and
substances.

TransMIT Gesellschaft für Technologietransfer mbH (www.transmit.de) being
the unit in charge of technology transfer at Justus-Liebig University in
Giessen is involved in carrying out this project.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]



---------------------------------------------------------------------

11.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


296447 11.11.2014